Movatterモバイル変換

[0]ホーム

Jump to content

Lucatumumab

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Lucatumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD40
Clinical data
ATC code	none
Identifiers
CAS Number	903512-50-5^N
ChemSpider	none
UNII	P0EP9VFC4R
KEGG	D08942^Y
Chemical and physical data
Molar mass	146 kg/mol
^NY (what is this?) (verify)

Lucatumumab (CHIR 12.12 or HCD122)^[1] is ahuman monoclonal antibody againstCD40^[2] development of which was discontinued byNovartis in 2013 after it was investigated for the treatment of various types ofcancer likemultiple myeloma andfollicular lymphoma.^[3]

It is an antagonist to CD40 that was created by scientists atChiron using Abgenix' XenoMousetransgenic mouse to generate fully human antibodies.^[4]^[5] It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.^[6]^[7]^[8] Novartis took over the project when it acquired Chiron in 2005.^[9]^[10]

Inin vitro studies, it inhibited cell proliferation induced by CD40 ligands and induced celllysis.^[11]

Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.^[1] The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.^[1]

References

[edit]

^^a ^b ^cHassan SB, Sørensen JF, Olsen BN, Pedersen AE (April 2014). "Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials".Immunopharmacology and Immunotoxicology.36 (2):96–104.doi:10.3109/08923973.2014.890626.PMID 24555495.S2CID 21840914.
^Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab,American Medical Association.
^"Lucatumumab". AdisInsight. Retrieved20 February 2017.
^"Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference". XOMA and Chiron vis Businesswire. December 2, 2004.
^Weng WK, Tong X, Luqman M, Levy R (16 November 2004)."(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma".Blood.104 (11): 3279.doi:10.1182/blood.V104.11.3279.3279.ISSN 0006-4971.
^"Chiron and Xoma in MAb deal - Pharmaceutical industry news".The Pharma Letter. March 8, 2004.. Part of Xoma's 10-K filed 2004-03-15.Index page at SEC Edgar.
^"Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA". Xoma via SEC Edgar.
^"Exhibit 10.2 Amended Research, Development and Commercialization Agreement".www.sec.gov. Xoma via SEC Edgar. May 26, 2005.
^Tansey B (November 1, 2005)."Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion".San Francisco Chronicle.
^"Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)". Xoma. November 10, 2008. Archived fromthe original on February 20, 2017. RetrievedFebruary 20, 2017.
^"Lucatumumab".NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). 2011-02-02. Retrieved20 February 2017.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pembrolizumab^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lucatumumab&oldid=1292680055"

Categories:

Hidden categories:

[8]ページ先頭